Engflag

Astyfer

Quick links to important sections

Astyfer

Astyfer_SV

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Astyfer

Quick Facts

Property Description
Active Ingredients Ferrous Fumarate, Folic Acid, B Vitamins, Vitamin C, Amino Acids
Form Oral preparations (Capsules and Syrup)
Pharmacological Class Haematinic Agent, Nutritional Supplement
Common Use Support for red blood cell formation, addressing nutritional deficiencies
Origin Derived and Synthetic Micronutrient Blend

What Type of Medicine is Astyfer?

Astyfer is defined as a specialized combination medicine that operates as a haematinic agent and a comprehensive nutritional supplement. Its fundamental purpose is to supply the critical components necessary to support and sustain the body's blood-forming capacity through erythropoiesis. The core components of this preparation, including Ferrous Fumarate and Folic Acid, are categorized as belonging to the class of antianemic preparations. The drug is intended for the oral route of administration and is typically presented as a syrup or in capsules.

Active Ingredients and Unique Composition

The formula is a complex blend of ten active ingredients, including the iron source Ferrous Fumarate, four crucial B vitamins (Thiamine, Pyridoxine, Folic Acid, Cyanocobalamin), Ascorbic Acid (Vitamin C), and three Amino Acids (L-histidine, L-lysine, Glycine). The inclusion of Ascorbic Acid is key, which enhances the absorption of nonheme iron from the digestive tract by converting it into a more soluble form. This formulation facilitates more effective utilization of the iron component. This unique combination, blending the iron with co-factors and amino acids, differentiates Astyfer from standalone iron supplements.

The General Purpose of the Astyfer Formulation

The general purpose of the Astyfer formulation is to provide a systematic provision of micronutrients to overcome nutritional deficiencies that impair oxygen transport. The strategic combination of Ferrous Fumarate with Folic Acid and Cyanocobalamin (Vitamin B12) supports the mineral requirement and provides the essential co-factors involved in the DNA synthesis central to red blood cell maturation. This integrated methodology supports the continuous renewal of the blood cell supply and maintains overall hematopoietic function, a typical use scenario for those experiencing chronic dietary gaps or physiological demands.

Regulatory References

  1. Folic Acid - MedlinePlus
  2. Iron - NIH Office of Dietary Supplements

What side effects are possible with Astyfer?

Possible side effects and safety information

The official safety documentation for this haematinic agent primarily focuses on the characteristics of its iron and folic acid components. The documented adverse reactions are categorized based on their observed frequency and the systems they affect, according to regulatory standards.

General Principles of Adverse Reactions

The most commonly documented adverse reactions, classified as Common in regulatory materials, are localized to the digestive tract. These effects are typical of oral iron preparations and include experiences such as nausea, vomiting, constipation, diarrhea, heartburn, and generalized stomach pain or cramps. A loss of appetite (anorexia) is also noted. These gastrointestinal effects are often temporary and may subside as the body adjusts to the treatment.

An expected, non-harmful finding associated with the iron component is the appearance of black or dark-colored stools, which results from unabsorbed iron passing through the digestive system.

Serious Safety Considerations

A critical and mandatory safety warning for all iron-containing products relates to the risk of fatal poisoning in young children. Accidental iron overdose is highlighted across regulatory documents as a leading cause of poisoning fatality in children under six years of age. Separately, serious allergic reactions (hypersensitivity) are classified as rare but may manifest as rash, swelling, or difficulty breathing.

Population and Condition-Specific Restrictions

Official labeling dictates specific constraints for certain conditions. The medicine is contraindicated in individuals with disorders of iron accumulation, such as hemochromatosis or hemosiderosis. It is also restricted in patients with untreated or undiagnosed pernicious anemia, as the folic acid component may mask the hematological signs of a Vitamin B12 deficiency, potentially allowing neurological damage to worsen. Caution is advised when the product is used in individuals with pre-existing gastrointestinal conditions, such as peptic ulcer disease.

Overdose and Emergency Response

Astyfer Overdose and when to seek help

Overdose involving this iron-containing product is officially defined as a life-threatening emergency primarily due to the severe toxicity of iron salts.

Overdose Scope Regulatory Documentation
Documented Presentations Acute overdose may manifest with severe abdominal pain, vomiting (potentially bloody), and diarrhea. Systemic effects include rapid heart rate, low blood pressure (hypotension), and neurological signs like drowsiness or lethargy.
Physiological Systems Affected The overdose profile documents damage to the gastrointestinal system, cardiovascular system (leading to shock), and the hepatic system (potential for acute liver failure).
Population-Specific Risk Accidental overdose of iron-containing products is specifically identified in official labeling as a leading cause of fatal poisoning in children younger than 6 years of age.
Emergency Response and Management Regulatory Documentation
Required Urgent Action Seek immediate medical attention for any suspected overdose. Call a doctor or poison control center immediately. Urgent help is required if the patient is observed to be passing out or experiencing trouble breathing.
Supportive Intervention Management involves symptomatic and supportive treatment. Specific procedures include medical chelation therapy (e.g., deferoxamine) and hospital monitoring of vital signs, serum iron levels, and metabolic indicators.

Official Overdose Statements:

  • Overdose may rapidly progress from acute symptoms to systemic failure, including shock, seizures, coma, and acute liver failure.
  • The documented management involves specific supportive measures, including the administration of a chelating agent.

Connection to the overall overdose profile: Regulatory documents classify this overdose as a critical event requiring mandatory, immediate medical intervention due to the risk of severe systemic failure and the high fatality risk in young children. The official profile explicitly details the progression of symptoms and the necessary, documented procedures for clinical management and observation.

Therapeutic Uses of Astyfer

What Astyfer Treats: Main Uses and Benefits

Astyfer is commonly used across conditions presenting with symptomatic nutritional deficiency anemia, including those stemming from inadequate intake of iron, Folic Acid, or Vitamin B12. In this context, the product provides support that helps ease the overall symptom burden by contributing to red blood cell formation.

This medication is applied in addressing symptom clusters associated with low circulating haemoglobin, such as persistent fatigue, physical weakness, and occasional signs of impaired oxygenation. Clinical scenarios where it is relevant often involve periods of high physiological demand, such as pregnancy and lactation, or following sustained blood loss from chronic conditions or surgery. The product is considered relevant in contexts involving chronic dietary gaps or situations where nutrient uptake stability becomes affected.

Supportive Focus: Symptom Management

Property Description
Symptom Management Assists with maintaining functional stability and may help patients cope more steadily with symptoms related to systemic imbalance, such as chronic fatigue and weakness.
Clinical Context Applied in clinical settings that involve nutritional deficiency or high-demand states like pregnancy or recovery from blood loss.

Regulatory References

  1. MedlinePlus Medical Encyclopedia overview on Iron deficiency anemia

Eligibility and Restrictions for Use

Astyfer is a nutritional supplement containing a combination of iron (Ferrous Fumarate), B-complex vitamins (including Folic Acid and Vitamin B12), Vitamin C, and amino acids (L-Histidine, L-Lysine, and Glycine). It is generally intended to address iron deficiency anemia and related nutritional gaps.

Official Eligibility and Contraindications

Category Regulatory Status (Official Statements)
Contraindicated Populations Individuals with a known hypersensitivity or allergy to any of the active ingredients or excipients in the Astyfer formulation.
Age-Related Rules Use in children should be managed with caution and strictly under medical supervision, particularly for products containing iron.
Pregnancy/Lactation Astyfer is generally considered safe for use during both pregnancy and lactation, often recommended to support the increased demands for iron and folic acid, but should always be taken as advised by a healthcare professional.
Conditions Requiring Caution Individuals with pre-existing conditions such as iron overload disorders or undiagnosed anemia (where Vitamin B12 deficiency has not been ruled out) should use this product with professional guidance.

Important Restriction

Do not use Astyfer as a sole treatment for pernicious anemia or other megaloblastic anemias caused by a deficiency of Vitamin B12, as the folic acid component may mask the hematological symptoms while allowing the neurological damage to progress.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Astyfer, which contains Ferrous Fumarate and Folic Acid, is primarily defined by documented effects on the absorption and plasma concentration of co-administered substances. The majority of clinically significant interactions result from gastrointestinal chelation, where the iron component reduces the amount of a co-administered drug that enters the bloodstream.

Documented Pharmacokinetic Interactions

Co-administration with Astyfer can reduce the therapeutic effect of several medications due to decreased absorption. This includes Quinolone and Tetracycline antibiotics, Thyroid Hormone replacements (like levothyroxine), Bisphosphonates, and certain Anti-Parkinsonian drugs (e.g., levodopa). Regulatory documentation requires mandatory time separation between doses to mitigate the reduction in plasma exposure.

Contraindications and Administration Constraints

Category Documented Constraint Impact on Exposure/Absorption
Contraindicated Combinations Co-administration is prohibited with Parenteral Iron Preparations. Risk of iron overload/toxicity
Timing-Based Separation Must be separated by specific intervals from Antacids, Tetracyclines, Quinolones, and Calcium supplements. Reduced absorption of both agents

Pharmacodynamic and Substance Interactions

The Folic Acid component may reduce the serum levels of certain anticonvulsant medications, and high-dose Folic Acid can officially obscure the diagnosis of Vitamin B12 deficiency (pernicious anemia) by masking hematological symptoms. Furthermore, substances like Coffee or Tea contain compounds that are documented to reduce iron absorption, requiring administration separation.

Mechanism of Action

Astyfer provides elemental iron, folic acid, cyanocobalamin (Vitamin B12), pyridoxine (Vitamin B6), and specific amino acids (L-Histidine, L-Lysine, Glycine) which function as precursors and cofactors in fundamental biological synthesis pathways. Ferrous iron is transported into enterocytes via the divalent metal transporter 1 (DMT1) channel in the duodenum. Intracellularly, iron is either stored bound to ferritin or transported into the circulation via ferroportin (FPN1). The circulating ferric form is bound to transferrin and delivered to target tissues, primarily erythroid progenitor cells in the bone marrow, where it is internalized via the transferrin receptor (TfR1) for incorporation into protoporphyrin to form heme.

Simultaneously, folic acid is converted to tetrahydrofolate, a cofactor for one-carbon transfers in the synthesis of purines and thymidylate, which are essential for DNA replication and cell division. Cyanocobalamin acts as a cofactor for the enzyme methionine synthase, regulating the conversion of N^5-methyltetrahydrofolate back to tetrahydrofolate, a key step in DNA synthesis and the maintenance of hematopoietic cell proliferation. The synergistic action of these components ensures the availability of required structural moieties and enzymatic cofactors, modulating the erythropoietic pathway and increasing the overall production of oxygen-carrying protein complexes in circulation.

Dosage and Administration Information

Astyfer is administered exclusively via the oral route in its available capsule and liquid forms. The preparation is intended to be swallowed whole and does not require dilution or reconstitution.

Standard Administration and Dosing

The standardized adult regimen is based on a unit dose of one capsule or 10 mL of liquid. This unit dose is typically administered once daily for maintenance, though therapeutic protocols may specify a twice-daily frequency. The entire course of treatment is guided by a specific duration principle: administration should continue for approximately three months after hemoglobin values return to the normal range to ensure the adequate replenishment of the body’s iron stores.

Contextual Usage Instructions

For optimal absorption, the dose is generally taken on an empty stomach, ideally one hour before or two hours after a meal. This timing is designed to maximize the uptake of the iron components. However, if the preparation causes gastric discomfort, the dose may be taken immediately with or following a meal. To ensure proper absorption, it is important to avoid consuming the medication within two hours of consuming tea, coffee, or dairy products, as these substances can inhibit iron uptake from the digestive tract. Each dose should be taken with a full glass of water, and individuals are generally advised to remain upright for at least 10 minutes following administration. The standard dosing regimen is applicable to adolescents aged 12 years and older and is commonly utilized during periods of pregnancy and lactation when medically indicated.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Astyfer Formulation

Evidence Base for Nutritional Iron Deficiency

The core components of the Astyfer formulation, primarily iron and folic acid, have been evaluated in numerous studies, including randomized controlled trials (RCTs) and systematic reviews, for individuals presenting with nutritional deficiencies. Studies primarily monitored outcomes related to systemic or functional imbalance, such as quantifying changes in objective blood markers, including Hemoglobin (Hb) levels and Serum Ferritin. Research highlights changes measured during the study period, typically over short-term intervals of 4 to 12 weeks.

Studies in Pregnancy and High Physiological Demand

The core components were evaluated in research contexts involving periods of high physiological demand, such as in pregnant women. This evidence base consists of systematic reviews and large-scale RCTs, often comparing combination iron and folic acid regimens against placebo or single supplements. Research examined the possibility of patterns related to the incidence of deficiencies and monitored outcomes related to specific maternal health indicators.

Findings describe an association between combination iron and folic acid supplementation and the patterns of Hemoglobin levels observed during pregnancy. However, the majority of this high-level, established evidence is based on standard, simple iron and folic acid preparations, which may introduce uncertainty when applied to this specific multi-ingredient complex.

Areas of Research Uncertainty and Gaps

A key limitation across the evidence landscape is that comparative evidence is lacking for the Astyfer multi-component formula when directly evaluated against simpler, single-component iron supplements in large-scale trials. While the general efficacy of the core ingredients is established, the research does not determine whether the amino acids and full vitamin blend significantly influence the outcome.

Follow-up durations were limited across many studies. This means that data for long-term use and maintenance remain insufficient.

Key Studies & References

  1. Antenatal care guidelines on Daily oral iron and folic acid supplementation (WHO)
  2. Ferrous fumarate (Oral Tablet) Drug Label Information - DailyMed (NIH)

Frequently Asked Questions (FAQ)

Common questions about Astyfer (FAQ)

Q: What is Astyfer used for?

A: According to official product information, Astyfer is indicated for the management and prevention of nutritional anemias, particularly those related to deficiencies in iron, B-group vitamins, or amino acids. It is also used to provide nutritional support that may assist in managing general weakness and fatigue.

Q: Does Astyfer help with general weakness and fatigue?

A: Regulatory documents indicate that Astyfer is prescribed for managing fatigue and general weakness, especially when these symptoms are associated with nutritional deficiencies. The official product information indicates that the ingredients are included to provide nutritional support that may assist in addressing the underlying nutritional causes of weakness and fatigue.

Q: What is the role of amino acids in Astyfer?

A: Regulatory documents state that amino acids like L-Lysine and L-Histidine serve as nutritional supplements. They are intended to support essential bodily functions and potentially assist in the utilization of other components, such as iron, as part of the overall nutritional support provided by the product.

Q: Can Astyfer be used during pregnancy or breastfeeding?

A: Official product information suggests that Astyfer may be suitable for use during pregnancy and lactation. As with any medication or supplement during these periods, usage should always be determined and supervised by a qualified healthcare professional.

Q: What is 'nutritional anemia'?

A: Nutritional anemia is a condition where the body has a lower-than-normal amount of healthy red blood cells due to a deficiency in essential nutrients. Astyfer is indicated for treating and preventing these types of anemias, specifically those related to deficiencies in iron, B-group vitamins, or certain amino acids.

How should Astyfer be stored and disposed of?

Astyfer's storage requirements are defined by regulatory labeling to protect the stability of its vitamin and iron components.

Storage Requirements

  • Temperature: The product must be stored below 25 C.
  • Environment: Storage must be in a cool, dark, and dry place, requiring protection from both light and moisture.
  • Child Safety: For safety, the medicine must be kept out of the sight and reach of children.
  • Packaging: It should remain in its original, light-protected container.

Disposal

Official disposal instructions require that any unused or expired Astyfer be discarded in accordance with local regulatory requirements for pharmaceutical waste. The product should not be disposed of into wastewater systems (sinks or toilets) unless specifically directed by local authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Astyfer found in:

A-Z Index: